PENETREX Drug Patent Profile
✉ Email this page to a colleague
When do Penetrex patents expire, and what generic alternatives are available?
Penetrex is a drug marketed by Sanofi Aventis Us and is included in one NDA.
The generic ingredient in PENETREX is enoxacin. There are three drug master file entries for this compound. Additional details are available on the enoxacin profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PENETREX?
- What are the global sales for PENETREX?
- What is Average Wholesale Price for PENETREX?
Summary for PENETREX
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 105 |
| Patent Applications: | 4,820 |
| DailyMed Link: | PENETREX at DailyMed |
US Patents and Regulatory Information for PENETREX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | PENETREX | enoxacin | TABLET;ORAL | 019616-004 | Dec 31, 1991 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Sanofi Aventis Us | PENETREX | enoxacin | TABLET;ORAL | 019616-005 | Dec 31, 1991 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for PENETREX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | PENETREX | enoxacin | TABLET;ORAL | 019616-004 | Dec 31, 1991 | ⤷ Sign Up | ⤷ Sign Up |
| Sanofi Aventis Us | PENETREX | enoxacin | TABLET;ORAL | 019616-005 | Dec 31, 1991 | ⤷ Sign Up | ⤷ Sign Up |
| Sanofi Aventis Us | PENETREX | enoxacin | TABLET;ORAL | 019616-005 | Dec 31, 1991 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for PENETREX
See the table below for patents covering PENETREX around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Poland | 120155 | ⤷ Sign Up | |
| Romania | 81940 | PROCEDEU PENTRU PREPARAREA UNOR DERIVATI DE 6-HALO-4-OXO-7-(1-PIPERAZINIL)-1, 8-NAFTIRIDINA (PROCESS FOR THE PREPARATION OF 6-HALO-4-OXO-7-(1-PYPERAZINYL)-1, 8-NAPHTYRIDINE DERIVATIVES) | ⤷ Sign Up |
| Poland | 235049 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for PENETREX
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2344130 | 2017C/031 | Belgium | ⤷ Sign Up | PRODUCT NAME: OZENOXACINE; AUTHORISATION NUMBER AND DATE: BE509591 20170519 |
| 2344130 | 132017000093887 | Italy | ⤷ Sign Up | PRODUCT NAME: OZENOXACIN(DUBINE); AUTHORISATION NUMBER(S) AND DATE(S): ES/H/414/01/DC, 20170519;045237017, 20170711 |
| 2344130 | 122017000073 | Germany | ⤷ Sign Up | PRODUCT NAME: OZENOXACIN; NAT. REGISTRATION NO/DATE: 97303.00.00 20170803; FIRST REGISTRATION: BELGIEN BE509591 20170517 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
